- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01055080
Insulin-free Cow Milk Formula in Prevention of Type 1 Diabetes Associated Autoimmunity - FINDIA Pilot Study (FINDIA)
January 22, 2010 updated by: Finnish Institute for Health and Welfare
Pilot Study of Dietary Prevention of Type 1 Diabetes Associated Beta-cell Autoimmunity in Children at Genetic Risk
The purpose of this study is to determine whether weaning to whey-based hydrolysed formula or essentially bovine insulin free whey-based FINDIA formula instead of standard cow's milk based formula is effective in the prevention of type 1 diabetes associated beta-cell autoimmunity in children at genetic risk of type 1 diabetes.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
987
Phase
- Not Applicable
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- ADULT
- OLDER_ADULT
- CHILD
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- HLA-conferred genetic susceptibility for type 1 diabetes
Exclusion Criteria:
- Pre-term, maternal diabetes with insulin treatment
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
PLACEBO_COMPARATOR: Cow's milk formula
|
Weaning to three different type of cow's milk formula when breast milk is not available during the first 6 months of life
|
|
ACTIVE_COMPARATOR: Bovine insulin-free whey based formula
|
Weaning to three different type of cow's milk formula when breast milk is not available during the first 6 months of life
|
|
ACTIVE_COMPARATOR: Whey-based hydrolysed formula
|
Weaning to three different type of cow's milk formula when breast milk is not available during the first 6 months of life
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Beta-cell autoantibodies
Time Frame: 3,6,12,24,36,48,60,72 months
|
3,6,12,24,36,48,60,72 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Outi Vaarala, MD PhD, Finnish Institute for Health and Welfare
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- de Goffau MC, Luopajarvi K, Knip M, Ilonen J, Ruohtula T, Harkonen T, Orivuori L, Hakala S, Welling GW, Harmsen HJ, Vaarala O. Fecal microbiota composition differs between children with beta-cell autoimmunity and those without. Diabetes. 2013 Apr;62(4):1238-44. doi: 10.2337/db12-0526. Epub 2012 Dec 28.
- Vaarala O, Ilonen J, Ruohtula T, Pesola J, Virtanen SM, Harkonen T, Koski M, Kallioinen H, Tossavainen O, Poussa T, Jarvenpaa AL, Komulainen J, Lounamaa R, Akerblom HK, Knip M. Removal of Bovine Insulin From Cow's Milk Formula and Early Initiation of Beta-Cell Autoimmunity in the FINDIA Pilot Study. Arch Pediatr Adolesc Med. 2012 Jul 1;166(7):608-14. doi: 10.1001/archpediatrics.2011.1559.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2002
Primary Completion (ACTUAL)
June 1, 2006
Study Completion (ACTUAL)
December 1, 2009
Study Registration Dates
First Submitted
January 22, 2010
First Submitted That Met QC Criteria
January 22, 2010
First Posted (ESTIMATE)
January 25, 2010
Study Record Updates
Last Update Posted (ESTIMATE)
January 25, 2010
Last Update Submitted That Met QC Criteria
January 22, 2010
Last Verified
January 1, 2010
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- FINDIA2002
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Beta-cell Autoimmunity
-
Shanghai 10th People's HospitalCompleted
-
University of British ColumbiaCompletedSickle Cell Disease | Beta-Thalassemia | Sickle Cell Trait | Sickle Cell-Beta Thalassemia | Sickle Cell-SS DiseaseCanada, Nepal
-
M.D. Anderson Cancer CenterWithdrawnSickle Cell Disease | Sickle Beta Thalassemia | Beta Thalassemia Major | Sickle Cell-SS Disease | Sickle Beta 0 Thalassemia | Sickle Beta Plus ThalassemiaUnited States
-
Hospices Civils de LyonActive, not recruiting
-
Hospital Universitari Vall d'Hebron Research InstituteHospital General Universitario Gregorio Marañon; Universitaire Ziekenhuizen... and other collaboratorsCompletedSickle Cell Disease | Hemoglobinopathies | Sickle Cell Anemia | Beta-Thalassemia | Sickle Beta Thalassemia | Alpha-Thalassemia | Beta Thalassemia Intermedia | Beta Thalassemia Major | Spherocytosis, Hereditary | Sickle Cell Hemoglobin C | Elliptocytosis, Hereditary | Stomatocytosis | Sickle-Cell; Hemoglobinopathy | Sickle Cell Hemoglobin... and other conditionsSpain
-
Novartis PharmaceuticalsRecruitingAutoimmunity, InflammationSpain, Bulgaria, United States, Czechia, Switzerland, China, Poland, Malaysia, Mexico, South Africa, India, Guatemala, Portugal, Russia, Brazil, Colombia, Greece, South Korea, Italy
-
Kenneth Ataga, MDAugusta UniversityCompletedSickle Cell Anemia | Sickle - Beta Thalassemia
-
HI-Bio, A Biogen CompanyCompletedImmune System Diseases | AutoimmunityUnited States
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedHematologic Diseases | Anemia, Sickle Cell | Beta-Thalassemia | Hematopoietic Stem Cell TransplantationUnited States, Canada
-
Nova Laboratories LimitedCompletedSickle Cell Disease | Sickle Cell Hemoglobin C | Sickle Cell-beta-thalassemia | Sickle-Cell; Hemoglobin Disease, ThalassemiaUnited Kingdom, Jamaica
Clinical Trials on Cow's milk formula
-
Mead Johnson NutritionFederal University of BahiaCompletedChild Nutrition SciencesBrazil
-
Meir Medical CenterSchneider Children's HospitalRecruitingCow Milk Allergy | NewbornsIsrael
-
Mead Johnson NutritionWithdrawnGrowthUnited States
-
Mead Johnson NutritionShanghai Children's Medical Center; Shanghai, ChinaCompletedAcute Respiratory Infection | Diarrheal DiseaseChina
-
Ausnutria Hyproca B.V.Not yet recruitingInfections | Quality of Life | Gastrointestinal Tolerance | Gastrointestinal Symptoms | AnthropometricsSaudi Arabia
-
Ausnutria Hyproca B.V.Completed
-
Mead Johnson NutritionFederal University of BahiaCompletedAcute Respiratory Infection | Diarrheal DiseaseBrazil
-
University of CopenhagenAnjo A/SCompletedObesity | Cardiovascular Disease | Metabolic Syndrome | Growth | Blood Pressure
-
Mead Johnson NutritionUniversity of North Carolina, Chapel HillTerminatedDeclarative MemoryUnited States
-
Mead Johnson NutritionUniversity of Kansas Medical CenterCompletedBehavioral Measures of ToleranceUnited States